Pensionfund Sabic Takes $2.19 Million Position in Gilead Sciences, Inc. $GILD

Pensionfund Sabic acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 17,800 shares of the biopharmaceutical company’s stock, valued at approximately $2,185,000.

Other hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Gilead Sciences during the 2nd quarter worth $2,150,268,000. Invesco Ltd. increased its position in Gilead Sciences by 12.0% during the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after buying an additional 1,618,453 shares during the last quarter. Amundi raised its holdings in Gilead Sciences by 18.2% during the second quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock valued at $1,167,221,000 after buying an additional 1,614,355 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of Gilead Sciences by 4.2% during the 3rd quarter. Legal & General Group Plc now owns 10,210,599 shares of the biopharmaceutical company’s stock worth $1,133,376,000 after acquiring an additional 414,454 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in shares of Gilead Sciences by 5.9% during the 3rd quarter. Ameriprise Financial Inc. now owns 7,148,405 shares of the biopharmaceutical company’s stock valued at $793,506,000 after acquiring an additional 400,002 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on GILD shares. Barclays began coverage on Gilead Sciences in a research report on Friday, February 20th. They issued an “equal weight” rating and a $155.00 price objective for the company. The Goldman Sachs Group raised their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research report on Thursday, January 8th. Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $103.00 to $118.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 11th. Bank of America set a $162.00 price target on Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, February 11th. Finally, Citigroup reiterated a “buy” rating on shares of Gilead Sciences in a research report on Friday, March 6th. Twenty-four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $157.62.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $144.23, for a total value of $432,690.00. Following the transaction, the insider directly owned 131,779 shares in the company, valued at $19,006,485.17. This represents a 2.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, March 16th. The stock was sold at an average price of $144.23, for a total transaction of $432,690.00. Following the sale, the chief financial officer directly owned 179,191 shares of the company’s stock, valued at $25,844,717.93. This represents a 1.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 309,280 shares of company stock valued at $44,068,850. 0.27% of the stock is owned by company insiders.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $138.11 on Wednesday. The firm has a market cap of $171.42 billion, a price-to-earnings ratio of 20.40, a PEG ratio of 1.80 and a beta of 0.37. The company has a 50 day moving average of $143.31 and a 200-day moving average of $128.32. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be paid a $0.82 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. Gilead Sciences’s payout ratio is 48.45%.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead announced a definitive agreement to acquire Ouro Medicines for up to $2.18 billion, adding OM336 (gamgertamig), a clinical-stage BCMAxCD3 T‑cell engager for autoimmune diseases — a move that broadens Gilead’s inflammation/immunology pipeline and gives the company a new modality in autoimmunity. Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
• Positive Sentiment: Deal coverage highlights collaboration plans (including work with a Belgian pharma/Galapagos on development), which could accelerate clinical development and de‑risk commercialization paths for the acquired asset. Gilead to buy biotech firm Ouro Medicines in over $2 billion deal
• Positive Sentiment: Sell‑side support remains constructive: Bank of America/other analysts have reiterated Buy views and see upside from Gilead’s HIV franchise and new immunology assets, supporting investor confidence in valuation upside. Buy Rating on Gilead Driven by HIV Franchise Momentum and Upside from Yeztugo and Biktarvy
• Neutral Sentiment: Media reports show varying deal-value figures (articles citing amounts from ~$1.68B to up to $2.18B), reflecting structure with upfront and milestone components — investors should watch the deal terms and milestone schedule for accounting/cash impact clarity. Gilead Sciences to Acquire Ouro Medicines in Up to $2.18 Billion Deal
• Neutral Sentiment: Short‑interest data feeds flagged a “large increase” in March but the reported figures are zero/NaN — this appears to be a data error and isn’t giving a reliable signal about bearish positioning. (Monitor confirmed short‑interest filings for any real changes.)
• Negative Sentiment: Acquisition risks: the deal carries integration, clinical, and milestone execution risk and uses up cash/commitments that could affect near‑term free cash flow; if OM336 fails to advance as expected, the acquisition premium could weigh on returns. Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.